To compare therapeutic effect of dibutyryl cyclic adenosine monophosphate calcium (DCAMC) on chronic heart failure (CHF) between different administration route .Methods :The 98 CHF patients were ran‐ domly and equally divided into intravenous drip (i .v.gtt) group and intramuscular injection group (i.m .) group , both groups received DCAMC via corresponding administration route based on routine anti heart failure treatment for 10d.Plasma level of N terminal pro brain natriuretic peptide (NT‐proBNP) ,left ventricular end diastolic dimen‐sion (LVEDd) ,LVEF before and after treatment ,and incidence of adverse reactions were observed and compared between two groups .Results :Compared with before treatment , there were significant reductions in plasma NT‐proBNP level [i.v.gtt group :(6846.23 ± 3856. 01)pg／ml vs.(2285.69 ± 2023.79)pg／ml ,i .m .group :(6151. 50 ± 5160.09) pg／ml vs.(2568.37 ± 2488.51)pg／ml] and LVEDd [i.v.gtt group :(4.78 ± 0.44 )cm vs.(4. 69 ± 0.43) cm ,i.m .group :(4.97 ± 0.64)cm vs .(4. 88 ± 0.62) cm] ,and significant rise in LVEF [i.v.gtt group :(59.49 ± 4.64)% vs.(60. 67 ± 4. 52)%,i.m.group :(57.67 ± 7.19)% vs.(58.94 ± 7.05)%] in two groups after treatment , P＝0.001 all.There were no significant difference in above indexes between two groups before and after treatment , P＞0. 05 all.There was no significant difference in incidence rate of adverse reactions between two groups , P＝1.000. Conclusion :DCAMC can improve cardiac function in CHF patients .Therapeutic effect of local intramuscular injection is equal with that of intravenous drip .